Merck Reports Phase 2b Data for Axicabtagene ciloleucel in Chronic lymphocytic leukemia

Merck today announced Phase 2b results for axicabtagene ciloleucel in patients with chronic lymphocytic leukemia. The study demonstrated that axicabtagene ciloleucel achieves high response rates compared to standard of care or placebo. These results provide important insights into the treatment of chronic lymphocytic leukemia and support the continued development of axicabtagene ciloleucel in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.